Publications

MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
Leuk Lymphoma 2018 Feb 22;59(2):505-508. Epub 2017 Jun 22.
b Lymphoid Malignancies Branch , Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.


Host-related immunodeficiency in the development of multiple myeloma.
Leuk Lymphoma 2017 Aug 9:1-6. Epub 2017 Aug 9.
b Myeloma Service, Department of Medicine , Memorial Sloan-Kettering Cancer Center , New York , NY, USA.

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
J Clin Oncol 2017 Jun 14;35(16):1803-1813. Epub 2017 Mar 14.
James N. Kochenderfer, Robert P.T. Somerville, Tangying Lu, Victoria Shi, Stephanie L. Goff, James C. Yang, Richard M. Sherry, Christopher A. Klebanoff, Udai S. Kammula, Constance M. Yuan, Mark J. Roschewski, Steven A. Feldman, Lori McIntyre, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD; Adrian Bot, John Rossi, Allen Xue, Marika Sherman, and Arianne Perez, Kite Pharma, Santa Monica, CA; Tatyana Feldman, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; and Jonathan W. Friedberg, University of Rochester School of Medicine, Rochester, NY.







Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.
Cytokine 2014 Oct 17;69(2):294-7. Epub 2014 Jul 17.
Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address:

Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.
J Clin Oncol 2014 Sep 14;32(25):2699-704. Epub 2014 Jul 14.
Brendan M. Weiss, University of Pennsylvania, Philadelphia, PA; Joseph Hebreo, Naval Medical Center San Diego, San Diego, CA; Daniel V. Cordaro, Mark J. Roschewski, Thomas Baker, Kevin C. Abbott, and Stephen W. Olson, Walter Reed National Military Medical Center, Bethesda, MD.

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Haematologica 2014 Jun 21;99(6):e81-3. Epub 2014 Mar 21.
Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA





OF